Vivozon Pharmaceutical Co Ltd
KOSDAQ:082800
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vivozon Pharmaceutical Co Ltd
Income from Continuing Operations
Vivozon Pharmaceutical Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
Vivozon Pharmaceutical Co Ltd
KOSDAQ:082800
|
Income from Continuing Operations
-₩28.6B
|
CAGR 3-Years
28%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-19%
|
|
|
SK Hynix Inc
KRX:000660
|
Income from Continuing Operations
₩42.9T
|
CAGR 3-Years
168%
|
CAGR 5-Years
55%
|
CAGR 10-Years
26%
|
|
|
DB HiTek Co Ltd
KRX:000990
|
Income from Continuing Operations
₩252.6B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
|
|
R
|
RFHIC Corp
KOSDAQ:218410
|
Income from Continuing Operations
₩35.5B
|
CAGR 3-Years
94%
|
CAGR 5-Years
87%
|
CAGR 10-Years
N/A
|
|
|
L
|
Leeno Industrial Inc
KOSDAQ:058470
|
Income from Continuing Operations
₩152B
|
CAGR 3-Years
10%
|
CAGR 5-Years
22%
|
CAGR 10-Years
17%
|
|
|
F
|
Fadu Inc
KOSDAQ:440110
|
Income from Continuing Operations
-₩91.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vivozon Pharmaceutical Co Ltd
Glance View
Vivozon Pharmaceutical Co., Ltd. engages in the manufacture and sale of compound semiconductors. The company is headquartered in Yongin, Gyeonggi-Do. The company went IPO on 2005-11-18. The firm operates its business through three segments. The Pharmaceutical Business segment is engaged in the manufacture and sale of finished medicines such as external skin preparations, antipyretic analgesic, anti-inflammatory drugs and antidiabetic drugs. The Optical Business segment is engaged in the manufacture and sale of finished products and lighting module sets such as general lighting and automotive lighting using light emitting diode (LED) light sources. The Cosmetics Business segment is engaged in the manufacture and sale of cosmetics and cosmetic ingredients.
See Also
What is Vivozon Pharmaceutical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
-28.6B
KRW
Based on the financial report for Sep 30, 2025, Vivozon Pharmaceutical Co Ltd's Income from Continuing Operations amounts to -28.6B KRW.
What is Vivozon Pharmaceutical Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-19%
Over the last year, the Income from Continuing Operations growth was -884%. The average annual Income from Continuing Operations growth rates for Vivozon Pharmaceutical Co Ltd have been 28% over the past three years , 2% over the past five years , and -19% over the past ten years .
